Bretylium tosilate

Generic Medicine Info
Prevention of arrhythmias in patients w/ recent MI. Concomitant use w/ digitalis glycosides, unless arrhythmia is unrelated to digitalis toxicity and resistant to other therapy.
Special Precautions
Patient w/ fixed cardiac output (e.g. severe aortic stenosis or pulmonary HTN), bradycardia. Renal impairment. Monitoring Parameters Monitor ECG, BP and renal function.
Adverse Reactions
Hypotension, dizziness, light-headedness, vertigo, transient increase in BP and heart rate, worsening of cardiac arrhythmias, nausea, vomiting; local tissue necrosis and muscle atrophy (IM).
Drug Interactions
May enhance the effects of sympathomimetics.
CIMS Class
ATC Classification
C01BD02 - bretylium tosilate ; Belongs to class III antiarrhythmics.
Disclaimer: This information is independently developed by CIMS based on bretylium tosilate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in